Navigation Links
Mylan Reports Adjusted Diluted EPS of $0.53 for the Quarter, an 18% Increase Over Prior Year Quarter; and $2.04 for the Year, a 27% Increase Over Prior Year
Date:2/21/2012

PITTSBURGH, Feb. 21, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced its financial results for the three months and year ended December 31, 2011.

Financial Results

  • Adjusted diluted EPS of $0.53 for the three months ended December 31, 2011 compared to $0.45 for the same prior year period, an increase of 18%;

  • Adjusted diluted EPS of $2.04 for the year ended December 31, 2011 compared to $1.61 for the prior year, an increase of 27%;

  • Total revenues of $1.53 billion for the three months ended December 31, 2011 compared to $1.43 billion for the same prior year period, an increase of 7%; Fourth quarter revenues were negatively impacted by foreign currency translation, as discussed further below.  The impact was 1% (approximately $18M) compared to the same prior year period, and 2.5% (approximately $39M) on a sequential quarter basis;

  • Total revenues of $6.13 billion for the year ended December 31, 2011 compared to $5.45 billion for the prior year, an increase of 12%;  

  • On a GAAP basis, diluted EPS of $0.30 for three months ended December 31, 2011 compared to $0.01 for the same prior year period;

  • On a GAAP basis, diluted EPS of $1.22 for the year ended December 31, 2011 compared to $0.68 for the prior year, an increase of 79%;

  • Adjusted cash provided by operating activities of $882 million for the year ended December 31, 2011 compared to $781 million for the prior year;

  • On a GAAP basis, cash flow from operating activities of $720 million for the year ended December 31, 2011 compared to $931 million for the prior year.

  • Heather Bresch, Mylan's Chief Executive Officer stated: "Our excellent financial results once again demonstrate our ability to deliver significant growth while continuing to manage the inherent challenges of our industry, as well
    '/>"/>

    SOURCE Mylan Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

    Related medicine technology :

    1. Mylan and Pfizer Announce Epinephrine Auto-injector Settlement Agreement
    2. Mylan to Change Name of Specialty Subsidiary From Dey Pharma to Mylan Specialty
    3. Mylan Actively Addressing Shortage of Preservative-Free Methotrexate Injection
    4. Mylan CEO Heather Bresch Testifies Before Congress in Support of Generic Drug User Fee Program and Urges Update of Federal Food, Drug and Cosmetic Act of 1938 to Create a Level Playing Field for Manufacturers
    5. Mylan Completes Acquisition of Two Limited-Competition Dermatological Products from Valeant
    6. Valeant Pharmaceuticals Completes Divestiture of Generic Dermatology Products to Mylan
    7. Mylan Receives Tentative FDA Approval for Generic Version of Lipitor®
    8. Mylan to Host Investor Day on Feb. 21, 2012, in New York City
    9. Mylan Launches Innovative Version of Antiepileptic Drug Levetiracetam
    10. Mylan Launches First Generic Version of Teveten® Tablets
    11. Mylan Receives Approval for First-to-File Generic Keppra XR® Extended-Release Tablets
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/21/2015)... YORK , April 21, 2015 EpiCast ... Summary Sepsis is a life-threatening complication arising from ... the infection damages its own tissues and organs. Anyone ... among children <1 year of age, older ... 2014). Global estimates for the year 2013 showed that ...
    (Date:4/21/2015)... -- Global cap & closure demand to ... and closures will exceed $55 billion in 2019. In unit ... Beverages will continue to account for well over half of ... smaller markets are expected to register faster growth. ... developed markets -- the US, Western Europe ...
    (Date:4/21/2015)... 21, 2015 Gary A. Puckrein , ... Quality Forum (NMQF), today will present an award ... Pharmaceutical Research and Manufacturers of America (PhRMA), for ... On behalf of PhRMA, and in conjunction with NMQF, ... build awareness, start conversations, and increase diversity in clinical ...
    Breaking Medicine Technology:EpiCast Report: Sepsis - Epidemiology Forecast to 2023 2EpiCast Report: Sepsis - Epidemiology Forecast to 2023 3World Caps & Closures Market 2World Caps & Closures Market 3National Minority Quality Forum to Award PhRMA President John Castellani for Leadership in Increasing Clinical Trial Diversity 2National Minority Quality Forum to Award PhRMA President John Castellani for Leadership in Increasing Clinical Trial Diversity 3
    ... Advanced Life Sciences,Holdings, Inc. (Nasdaq: ADLS ... with the National Institute of Allergy and ... biodefense,research, under which the NIAID will conduct ... as a treatment for,anthrax and other high-priority ...
    ... Double-Blind Study Targets Biomarker-Defined Population, BERKELEY ... GNTA ) announced that the first ... Phase 3 trial of Genasense,(oblimersen sodium) Injection ... is a randomized, double-blind, placebo-controlled study in ...
    Cached Medicine Technology:Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 2Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 3Advanced Life Sciences Collaborates with U.S. Government to Study Cethromycin as Treatment for Anthrax and Other High-Priority Biodefense Agents 4Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 2Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 3Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 4Genta Initiates Phase 3 AGENDA Trial of Genasense(R) for Patients with Advanced Melanoma 5
    (Date:4/21/2015)... April 21, 2015 On April 2, ... Trying to Achieve Kylie Jenner Lips With ... have injured themselves while attempting an at-home lip ... Twitter is that creating an airlock around one’s mouth ... to plump and achieve Kylie Jenner’s now famous pout. ...
    (Date:4/21/2015)... Texas (PRWEB) April 22, 2015 ... Review, H1 2015” provides comparative analysis on ... report strengthens R&D pipelines by identifying new ... best-in-class products. Complete report with TOC is ... The report also reviews key players involved ...
    (Date:4/21/2015)... The California Healthcare Institute (CHI), ... sciences organizations, released the following statement by CHI ... Assembly Bill (AB) 463: , “As innovators in ... of treatments and cures for patients with serious ... AB 463, the so-called Pharmaceutical Cost Transparency Act ...
    (Date:4/21/2015)... Vancouver, BC (PRWEB) April 21, 2015 ... offers complimentary pick-up and delivery for clients that avail ... South Surrey by Angelo’s is done with hi-tech equipments, ... inconvenience for customers. They use all natural, high pressure ... as well as hand washing for area rugs made ...
    (Date:4/21/2015)... Danvers, MA (PRWEB) April 21, 2015 ... managed mobility services, has been recognized by the Boston ... Massachusetts. The ranking was announced at a recent ... Journal’s annual list of the fastest-growing private companies in ... held businesses in the state that recorded the fastest ...
    Breaking Medicine News(10 mins):Health News:Celebrity Cosmetic Surgeon Comments on Report of Teen Girls Injuring Themselves Attempting Kylie Jenner-Inspired Twitter Challenge 2Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 2Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 3Health News:Pulmonary Embolism Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com 4Health News:California Healthcare Institute Statement on AB 463 2Health News:California Healthcare Institute Statement on AB 463 3Health News:Angelo’s FabriClean Now Offers Area Rug Cleaning in South Surrey with Complimentary Pick-Up and Delivery 2Health News:Wireless Analytics Ranked as 25th Fastest Growing Private Company in Massachusetts 2
    ... 2 MedWaves, Inc. announces the receipt of ... is in addition to having already received U.S. ... Microwave Coagulation/Ablation System for surgical applications. The system ... interventional radiologists to treat soft tissue problems, such ...
    ... BEACH, Va., Feb. 2 AMERIGROUP Corporation (NYSE: ... plan in the State of Nevada began offering healthcare ... Children,s Health Insurance (SCHIP) programs beginning February 1, 2009. ... of Nevada," said James G. Carlson, AMERIGROUP Chairman and ...
    ... in customer and technical supportPORTLAND, Ore., Feb. 2 ... Vice President of Customer Support. With nearly 20 years ... managing customer inquiries, special service requests, and technical support ... leadership, she has also developed new programs to smooth ...
    ... Opportunity Partners, LLC ("Xmark"), the sole member of the investment ... Ltd., has, in the past, sent letters to the Board ... setting forth its dissatisfaction with the company,s corporate governance, management ... opportunity to respond to the Form 8-K filed by the ...
    ... Mich., Feb. 2 Dorothy Carpenter had stomach problems her ... or pasta could lead to terrible pain.Her illness went undiagnosed ... System physician recognized it as celiac disease. By then her ... forced doctors to remove part of her small intestine."I,ve been ...
    ... JOLLA, Calif., Feb. 2 Transdel Pharmaceuticals, ... ), a specialty pharmaceutical company focused on ... has retained FLP Pharma, a Georgia-based pharmaceutical ... especially the out-licensing of its lead product ...
    Cached Medicine News:Health News:MedWaves, Inc. Announces Receipt of MDD CE Certification and Additional U.S. FDA 510(k) Clearance to Market Its Patented Microwave Coagulation/Ablation System and Devices 2Health News:AMERIGROUP Health Plan in Nevada Begins Serving Medicaid Enrollees 2Health News:GI Condition Once Thought Rare is Common in U.S. 2Health News:GI Condition Once Thought Rare is Common in U.S. 3Health News:Transdel Pharmaceuticals, Inc. Retains FLP Pharma to Lead Business Development Activities 2Health News:Transdel Pharmaceuticals, Inc. Retains FLP Pharma to Lead Business Development Activities 3
    Rapid, visual assay for the presumptive qualitative detection of Respiratory Syncytial Virus (RSV) directly from nasopharyngeal specimens in neonatel and pediatric patients....
    Rapid immunochromatographic membrane test for RSV. Accepts nasopharyngeal washes, aspirates, and swabs....
    A direct enzyme immunoassay for detection of gr. A rotavirus in fecal specimens....
    ELISA for Anti-Proteinase 3 PR3 (cANCA)....
    Medicine Products: